Advanced Solid Tumor
Conditions
Keywords
Solid tumor, Advanced tumor, Profiling panel
Brief summary
The PROFILER 02 program is a multicenter, randomized, prospective cohort study aiming to compare the clinical relevance of a large Next-generation sequencing (NGS) panel (FondationOne or FOne panel) versus a limited NGS panel (CONTROL or CTL panel) in patients with advanced solid tumors. This study will allow adapting the therapeutic management of these patients, if needed, by giving them recommended therapies (commercialized or in ongoing clinical trials), based on the recommendations of the Molecular Tumor Board (MTB).
Detailed description
The genetic and immunologic profile of the tumor will be determined from archival or fresh collected tumor sample. For each patient, the tumor genomics data will be reviewed, at time of documented progressive disease, independently by a dedicated MTB to make a recommendation of therapy for a given patient based on its molecular profile. First, the genomics data issued from the panel defined by the randomization will be reviewed and recommended therapy resulting from randomization will be revealed to the Investigator. If a recommended therapy can be identified, this therapy will be recommended. If none recommended therapy can be identified, the 2nd panel performed will then be reviewed. In case of confirmed clinical or radiological progression (at Investigator's discretion) and/or unacceptable toxicity as per Investigator judgment during the line of therapy recommended by the MTB, the results of the second panel will be reviewed by MTB. Based on all genomics data available (i.e. randomized and 2nd panels), the MTB will recommend other treatment options. All results will be disclosed to Investigator in order to offer other treatment options.
Interventions
GENETICBlood and tumor samples
Evaluation of the added value of a large molecular profiling panel versus a limited molecular profiling panel
Sponsors
Roche Pharma AG
Centre Leon Berard
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
* Arm A: Tumor-based genomics according to the 324 cancer-related genes Next Generation Sequencing (NGS) panel from Foundation One (FOne panel). * Arm B: Tumor-based genomics according to the 87 cancer-related genes NGS panel performed at Centre Leon Berard Unité de Caractérisation Tumorale (CONTROL panel). Both panels will be performed concomitantly for all patients using the same patient tumor specimen.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female patient aged ≥ 18 years at time of inform consent signature. * Currently treated by a first or a second line of chemotherapy for their advanced cancer (local relapse or metastatic; Immunotherapies, Endocrine therapies and Targeted therapies are not considered as a line of chemotherapy). * Histologically confirmed diagnosis of advanced (local relapse or metastatic), incurable solid tumors from any histological types (except those listed in
Exclusion criteria
3). * I4. Availability of an adequate tumor sample to be sent imperatively to the CLB within 15 days after ICF signature by order of preference either (i1) a tumor archival FFPE block not older than 3 months prior to ICF signature or if not available :(ii2) a dedicated biopsy from one accessible lesion visible by medical imaging and accessible to percutaneous sampling with a diameter of at least 10 mm or if not feasible (3) an archival tumor sample (primary tumor or metastatic lesion) not older than 3 years at time of ICF signature. Quality (at least 20-30% of tumor cells) and quantity (sample size surface area \> 5mm2 and \> 90um depth) of the tumor sample have to be confirmed mandatorily within 7 days by a central pathological review before confirmation of inclusion. * Patient's disease which is not susceptible to progress during the next 45 days following the ICF signature. * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1. * Adequate organ and marrow function based on a medical records (within 21 days before randomization) as defined below : * Hemoglobin ≥ 9.0 g/dL * Absolute neutrophil count (ANC) ≥ 1.5 x 109/L * Platelets ≥ 100 x 109/L * Lymphocyte count ≥ 1 x 109/L * Serum creatinine CL \> 50 mL/min per 1.73m2 using MDRD or CKD-EPI * AST and ALT ≤ 2.5 Upper Limit Normal (ULN) (up to 5 ULN may be tolerated in case of liver metastases) * Serum bilirubin ≤ 1. 5 ULN (in the absence of Gilbert's syndrome). * Patient should understand, sign, and date the written ICF prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol. * Patient must be covered by a medical insurance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Compare the proportion of patients for whom a genomically identified recommended therapy could be initiated using the large NGS panel from FoundationOne versus the limited CONTROL panel. | 28 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Compare in the 2 randomization arms the proportion of patients for which a genomically identified recommended therapy is effectively initiated. | 28 months | — |
| Describe in both arms the number of patients for whom a genomically identified recommended therapy was available but not initiated. | 28 months | — |
| Evaluate proportion of patients who could have been initiated a recommended therapy considering only the INCa panel. | 28 months | Evaluate proportion of patients with at least one actionable alteration and for whom a genomically identified recommended therapy could have been initiated considering only the INCa panel with only 16 cancer-related genes already included in CONTROL panel |
| Progression-Free Survival (PFS) | 24 months | Measured from the date of study drugs start to the date of the first objective radiological disease progression using RECIST 1.1 or death. |
| Compare in the 2 randomization arms the number of patients with at least one actionable alteration. | 28 months | — |
| Duration of response (DoR) | 24 months | Calculated from date of first documented objective response (i.e., Complete Response or Partial Response) until date of first documented progression disease (measurements according to RECIST 1.1 criteria). |
| Patient Quality Of Life | 12 months | Measured by the questionnaire EuroQoL-5Dimension-3L |
| Perform a health economic evaluation | 12 months | A Cost-Effectiveness and a Cost-utility Analyses comparing the two molecular profiling strategies. |
| Overall response Rate (ORR) | 24 months | the most clinically favorable response recorded from the start of a recommended therapy until the end of treatment, according to RECIST 1.1 |
Countries
France
Outcome results
None listed